Jon Jarløv Rasmussen

Jon Jarløv Rasmussen

Auto-generated profile, based on publicly available information

Jon Jarløv Rasmussen

Department of Endocrinology, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2016 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
AJAnders Jorsal
Anders Jorsal
CKCaroline Kistorp
Caroline Kistorp
PHPernille Holmager
Pernille Holmager
RTRasmus Stilling Tougaard
Rasmus Stilling Tougaard
RNRoni Nielsen
Roni Nielsen
LTLise Tarnow
Lise Tarnow

17 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJon Jarløv Rasmussen
Jon Jarløv Rasmussen
CSChristian Selmer
Christian Selmer
PØPeter Østergren
Peter Østergren
KPKaren Boje Pedersen
Karen Boje Pedersen
MSMorten Schou
Morten Schou
CKCaroline Kistorp
Caroline Kistorp
Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of AAS abuse on reproductive hormone levels and symptoms suggestive of hypogonadism in current and former AAS abusers. This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. All participants were aged 18–50 years and were involved in recreational strength training. Reproductive hormones (FSH, LH, testosterone, inhibin B and anti-Müllerian hormone (AMH)) were measured using morning blood samples. Symptoms of hypogonadism (depressive symptoms, fatigue, decreased libido and erectile dysfunction) were recorded systematically. Former AAS abusers exhibited significantly lower median (25th –75th percentiles) total and free testosterone levels than control participants (total testosterone: 14.4 (11.9–17.7) nmol/l vs. 18.8 (16.6–22.0) nmol/l) (P < 0.01). Overall, 27.2% (13.3; 45.5) of former AAS abusers exhibited plasma total testosterone levels below the lower reference limit (12.1 nmol/l) whereas no control participants exhibited testosterone below this limit (P < 0.01). Gonadotropins were significantly suppressed, and inhibin B and AMH were significantly decreased in current AAS abusers compared with former AAS abusers and control participants (P < 0.01). The group of former AAS abusers had higher proportions of participants with depressive symptoms ((24.2%) (11.1; 42.2)), erectile dysfunction ((27.3%) (13.3; 45.6)) and decreased libido ((40.1%) (23.2; 57.0)) than the other two groups (trend analyses: P < 0.05). Former AAS abusers exhibited significantly lower plasma testosterone levels and higher frequencies of symptoms suggestive of hypogonadism than healthy control participants years after AAS cessation. Current AAS abusers exhibited severely decreased AMH and inhibin B indicative of impaired spermatogenesis.

1 September 2018 in American Heart Journal
Verified
Journal Article
Closed access
JRJon J. Rasmussen
Jon J. Rasmussen
MSMorten Schou
Morten Schou
PMPer L. Madsen
Per L. Madsen
CSChristian Selmer
Christian Selmer
MJMarie L. Johansen
Marie L. Johansen
CKCaroline Kistorp
Caroline Kistorp

1 February 2018 in Journal Of Hypertension
Verified
Journal Article
Closed access
JRJon J. Rasmussen
Jon J. Rasmussen
MSMorten Schou
Morten Schou
PMPer L. Madsen
Per L. Madsen
CSChristian Selmer
Christian Selmer
MJMarie L. Johansen
Marie L. Johansen
CKCaroline Kistorp
Caroline Kistorp
Abuse of anabolic androgenic steroids (AAS) is prevalent among recreational athletes and adverse effects on blood pressure (BP) and arterial stiffness could be substantial. Testosterone decreases natriuretic peptides which are key components in BP-regulation and may impair BP-homeostasis in AAS abusers. To investigate BP and aortic stiffness in relation to natriuretic peptides among current AAS abusers, former AAS abusers and controls. In this cross-sectional study, 37 current AAS abusers, 33 former AAS abusers and 30 controls were included. All participants were men involved in recreational strength training. We used 24-h BP monitoring, assessed proximal aorta distensibility index (ADI) by MRI and obtained overnight fasting blood samples to measure: midregional proatrial natriuretic peptide (MR-proANP), aldosterone, noradrenaline and copeptin. Current AAS abusers exhibited higher mean (95% confidence interval) 24-h systolic BP than controls [132 (129; 135) versus 124 (120; 128) mmHg, P = 0.005] and systolic hypertension was more frequent among current AAS abusers than controls (51 versus 17%, P = 0.009). ADI was lower among both current and former AAS abusers suggesting higher aortic stiffness; %-difference (95% confidence interval) from controls: −21% (−35; −5) and −21% (−36; −4), P < 0.05. Plasma MR-proANP was decreased, whereas aldosterone and noradrenaline were increased among current AAS abusers compared with former AAS abusers and controls. Decreased MR-proANP was independently associated with increased systolic BP and reduced ADI in multivariate linear regressions. Current AAS abusers displayed increased 24-h systolic BP and decreased plasma MR-proANP. Both current and former AAS abusers exhibited higher aortic stiffness.

8 June 2017 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
JRJon Jarløv Rasmussen
Jon Jarløv Rasmussen
MSMorten Schou
Morten Schou
CSChristian Selmer
Christian Selmer
MJMarie Louise Johansen
Marie Louise Johansen
FGFinn Gustafsson
Finn Gustafsson
CKCaroline Kistorp
Caroline Kistorp

1 March 2020 in Clinical Biochemistry
Verified
Journal Article
Closed access
MPMartine Paquette
Martine Paquette
DGDany Gauthier
Dany Gauthier
ACAnn Chamberland
Ann Chamberland
APAnnik Prat
Annik Prat
EREmanuella De Lucia Rolfe
Emanuella De Lucia Rolfe
ABAlexis Baass
Alexis Baass